Recruiting Scleroderma Studies in Aurora
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this...
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
This study investigates the efficacy and safety of belimumab compared to placebo, in addition to standard therapy, for the treatment of participants with systemic sclerosis associated interstitial lun...
About Scleroderma Clinical Trials in Aurora
Scleroderma is an autoimmune connective tissue disease characterized by hardening and tightening of the skin and connective tissues. Systemic sclerosis can also affect internal organs including lungs, kidneys, and heart. Treatment is directed at specific symptoms and organ involvement.
There are currently 2 scleroderma clinical trials recruiting participants in Aurora, CO. These studies are seeking a combined 606 participants. Research is being sponsored by AstraZeneca, GlaxoSmithKline. Clinical trial participation is free and participants receive study-related medical care at no cost.
Scleroderma Clinical Trials in Aurora — FAQ
Are there scleroderma clinical trials in Aurora?
Yes, there are 2 scleroderma clinical trials currently recruiting in Aurora, CO. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Aurora?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Aurora research site will contact you about next steps.
Are clinical trials in Aurora free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Aurora studies also compensate for your time and travel.
What scleroderma treatments are being tested?
The 2 active trials in Aurora are testing new therapies including novel drugs, biologics, and treatment approaches for scleroderma.
Data updated March 2, 2026 from ClinicalTrials.gov